NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1
FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm2
The US Food and Drug Administration (FDA) has approved the expanded use area for Almirall’s drug Klisyri (tirbanibulin) to up to 100 cm² for the treatment of actinic keratosis (AK) on the face or scalp.
A year after Almirall shared survey results showing that a vast majority of people are unaware of actinic keratosis, the most common precursor of skin cancer, and bumped up its educational efforts, the Spanish pharma’s work is still far from done.
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first quarter of 2024 which continues to be driven by the dermatology business in Europe. Net Sales increased by 6.6% to a total of €247.4 MM, EBITDA was €52.5 MM (increase of 1.4% YoY) driven by higher sales growth, with a gross margin of 63.5%. Dermatology sales in Europe increased by 18.1% to a total of €113MM. Continued strong investments in supporting the Ebglyss launch and our R&D efforts (10.7% of Net Sales).
Novo Licenses to Almirall Potential First-in-Class Antibody Candidate
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
Almirall Initiates First Phase I Clinical Study of ALM223